ArticleEuropean journal of histochemistry : EJH2011
Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy.
Article in European journal of histochemistry : EJH, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Regulation of Inducible Nitric Oxide Synthase (NOS2) Expression in Healthy and Inflamed Bowel: A Narrative Review.International journal of molecular sciences · 2026Review
- Cellular Stress and Immune Activation in Celiac Disease: Is the Chaperone System a Key Player?Biology · 2026Review
- The Multiple Roles of Heat Shock Proteins in the Development of Inflammatory Bowel Disease.Current molecular medicine · 2025Review
- 3D Printed Personalized Colon-targeted Tablets: A Novel Approach in Ulcerative Colitis Management.Current drug delivery · 2024Review
- Inflammatory Bowel Diseases: An Updated Overview on the Heat Shock Protein Involvement.International journal of molecular sciences · 2023Review
- Article
- Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophorae Decoction.Current pharmaceutical design · 2022Article
- Advances of Heat Shock Family in Ulcerative Colitis.Frontiers in pharmacology · 2022Review
- Numerical modelling and experimental verification of thermal effects in living cells exposed to high-power pulses of THz radiation.Scientific reports · 2021Article
- Heat Shock Protein 70 as a Double Agent Acting Inside and Outside the Cell: Insights into Autoimmunity.International journal of molecular sciences · 2020Review
- The Functions and Therapeutic Potential of Heat Shock Proteins in Inflammatory Bowel Disease-An Update.International journal of molecular sciences · 2019Review
- Elongated Flexuous Plant Virus-Derived Nanoparticles Functionalized for Autoantibody Detection.Nanomaterials (Basel, Switzerland) · 2019Article
- Article
- Hsp60 as a Novel Target in IBD Management: A Prospect.Frontiers in pharmacology · 2019Review
- Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.World journal of gastroenterology · 2018Review
- Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies.Pharmacogenomics and personalized medicine · 2017Review
- Emerging Roles for Noncanonical NF-κB Signaling in the Modulation of Inflammatory Bowel Disease Pathobiology.Inflammatory bowel diseases · 2016Review
- Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.Mucosal immunology · 2016Review
- Gut epithelial inducible heat-shock proteins and their modulation by diet and the microbiota.Nutrition reviews · 2016Review
- Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) characterized by damage of large bowel mucosa and frequent extra-intestinal autoimmune comorbidities. The role played in IBD pathogenesis by molecular chaperones known to interact with components of the immune system involved in inflammation is unclear. We previously demonstrated that mucosal Hsp60 decreases in UC patients treated with conventional therapies (mesalazine, probiotics), suggesting that this chaperonin could be a reliable biomarker useful for monitoring response to treatment, and that it might play a role in pathogenesis. In the present work we investigated three other heat shock protein/molecular chaperones: Hsp10, Hsp70, and Hsp90. We found that the levels of these proteins are increased in UC patients at the time of diagnosis and decrease after therapy, supporting the notion that these proteins deserve attention in the study of the mechanisms that promote the development and maintenance of IBD, and as biomarkers of this disease (e.g., to monitor response to treatment at the histological level).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.